ARTICLES BY MATTHEW PILLAR

• Bioprocessing Technology: You Are The Standard

  5/28/2024

  Single-use bioprocessing equipment engineer and expert Paul Priebe has some advice for you. Next time you catch yourself questioning an equipment standard (or the lack thereof), take a good look in the mirror. 

• 1 In 300 People In The U.S. Is Living With HIV. That's Not Okay With Jeff Galvin.

  2/13/2024

  By modifying CD4 T cells using miRNA, Jeff Galvin’s company thinks it can deliver a functional cure for HIV. Here’s the ongoing story of Addimmune and its unique clinical strategy.

• Why RNA Is Good For Business

  7/3/2023

  Early last year, Nutcracker Therapeutics landed a $170 million Series C to further its work developing an RNA drug development platform. Learn how scientist-turned Chief Business Officer Geoff Nosrati is lifting the company above the cacophony of companies rallying around the therapeutic potential of RNA.

• Biomanufacturing Capacity Crunch: It's The Supply Chain's Fault

  10/7/2022

  What's behind the protracted biopharma manufacturing capacity crunch, when will it end, and what are manufacturers doing to keep supply on track? During Biotech Week in Boston ad BioProcess International, CDMOs and sponsors weighed in.